# Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Source: https://onco.cc/trials/nct02065869/  
OnCo record `nct02065869` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.

## Summary

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant is a phase 1/2 interventional study registered as NCT02065869 by Bellicum Pharmaceuticals, with 187 participants enrolled, started 2014-04. Conditions recorded: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia and Anemia, Sickle Cell. Interventions recorded: BPX-501 T cells and Rimiducid.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02065869
- Phase: 1/2
- Setting: Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 187

## Sources

- ClinicalTrials.gov NCT02065869: https://clinicaltrials.gov/study/NCT02065869

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct02065869.json